首页> 外文OA文献 >FRI0174 SUBCUTANEOUS DOSING OF THE NOVEL ANTI-CD40 ANTIBODY ISCALIMAB ACHIEVES TARGET DRUG EXPOSURE AND CLINICAL EFFICACY IN PRIMARY SJÖGREN’S SYNDROME; RESULTS OF A PHASE IIA RANDOMISED OPEN LABEL TWO ARM PARALLEL GROUP TRIAL

【2h】

FRI0174 SUBCUTANEOUS DOSING OF THE NOVEL ANTI-CD40 ANTIBODY ISCALIMAB ACHIEVES TARGET DRUG EXPOSURE AND CLINICAL EFFICACY IN PRIMARY SJÖGREN’S SYNDROME; RESULTS OF A PHASE IIA RANDOMISED OPEN LABEL TWO ARM PARALLEL GROUP TRIAL

机译：Fri0174新型抗CD40抗体的皮下给药Iscalimab达到原发性Sjögren综合征的靶药暴露和临床疗效; IIA的结果随机开放标签两臂并联组试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Benjamin Fisher; Antónia Szántó; Wan Fai Ng; Michele Bombardieri; Maximilian Posch; Athena Papas; Arwa Farag; Thomas Daikeler; Bettina Bannert; Alan Kivitz; Steven Carsons; David Isenberg; Francesca Barone; Simon J. Bowman; Pascal Espie; Grazyna Wieczorek; Pierre Moulin; David Floch; Cyrielle Dupuy; Amanda Nguyen; Andrew Wright; Michael Rotte; James Rush; Peter Gergely;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Eligibility for clinical trials in primary Sj?gren’s syndrome: lessons from the UK Primary Sj?gren’s Syndrome Registry [J] . ClareOni, SherylMitchell, KatherineJames, Rheumatology . 2017,第12期

机译：初级SJ临床试验的资格？GREN的综合征：来自英国初级SJ的课程？GREN的综合征注册表
2. First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody [J] . Nature reviews Cancer . 2020,第2期

机译：一中临床试验评估异丙石的药代动力学，药效动物，安全性和耐受性，抗CD40单克隆抗体
3. The Sjögren's Syndrome Damage Index—a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome [J] . R. J. Barry1 N. Sutcliffe2 D. A. Isenberg3 E. Price4 F. Goldblatt3 M. Adler3 A. Canavan4 J. Hamburger5 A. Richards5 M. Regan6 K. Gadsby6 S. Rigby7 A. Jones8 R. Mathew8 D. Mulherin9 A. Stevenson9 P. Nightingale10 S. Rauz1 and S. J. Bowman11 Rheumatology . 2008,第8期

机译：干燥综合征综合症指数—一种用于原发性干燥综合征的临床试验和观察研究的损伤指数
4. Efficacy and safety of abatacept for patients with Sjögrens syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjögrens syndrome Endocrinopathy (ROSE) trial—an open-label one-year prospective study—Interim analysis of 32 patients for 24 weeks [O] . Hiroto Tsuboi, Isao Matsumoto, Shinya Hagiwara, -1

机译：阿巴西普对类风湿性关节炎干燥综合征患者的疗效和安全性：类风湿性关节炎Orencia试验用于干燥综合征的内分泌病（ROSE）试验（一项开放性前瞻性前瞻性研究）对32例患者进行了为期24周的中期分析
5. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study [O] . Benjamin A Fisher, Antonia Szanto, Wan-Fai Ng, 2020

机译：评估抗CD40抗体异霉素在原发性Sjögren综合征患者中：多期，随机，双盲，安慰剂控制，概念证明研究

FRI0174 SUBCUTANEOUS DOSING OF THE NOVEL ANTI-CD40 ANTIBODY ISCALIMAB ACHIEVES TARGET DRUG EXPOSURE AND CLINICAL EFFICACY IN PRIMARY SJÖGREN’S SYNDROME; RESULTS OF A PHASE IIA RANDOMISED OPEN LABEL TWO ARM PARALLEL GROUP TRIAL

著录项

引文网络

相似文献

相关主题

期刊订阅